Cargando…
A dual-targeting ruthenium nanodrug that inhibits primary tumor growth and lung metastasis via the PARP/ATM pathway
BACKGROUND: Many studies have found that ruthenium complexes possess unique biochemical characteristics and inhibit tumor growth or metastasis. RESULTS: Here, we report the novel dual-targeting ruthenium candidate 2b, which has both antitumor and antimetastatic properties and targets tumor sites thr...
Autores principales: | Lu, Yu, Zhu, Di, Gui, Lin, Li, Yuanming, Wang, Wenjing, Liu, Jiawang, Wang, Yuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063440/ https://www.ncbi.nlm.nih.gov/pubmed/33892746 http://dx.doi.org/10.1186/s12951-021-00799-3 |
Ejemplares similares
-
Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition
por: Aguilar-Quesada, Rocío, et al.
Publicado: (2007) -
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition
por: D’Ambrosio, Concetta, et al.
Publicado: (2022) -
RGD Peptide and PAD4 Inhibitor-Loaded Gold Nanorods for Chemo-Photothermal Combined Therapy to Inhibit Tumor Growth, Prevent Lung Metastasis and Improve Biosafety
por: Lu, Yu, et al.
Publicado: (2021) -
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
por: Gilardini Montani, Maria Saveria, et al.
Publicado: (2013) -
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
por: Yusoh, Nur Aininie, et al.
Publicado: (2020)